FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 315:538-542 August 28, 1986 Number 9 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We used a semisolid culture assay to quantitate leukemia cells in the bone marrow of patients with childhood acute lymphoblastic leukemia (ALL). In bone marrow cultures from 40 patients with newly diagnosed disease, the colonies that developed in vitro consisted of lymphoblasts with the same surface markers and abnormal karyotype as the original diagnostic marrow specimens. We also studied marrow cultures from 13 patients in chemotherapy-induced remission; 6 of these, including 1 obtained from a patient during successful engraftment after marrow transplantation, also yielded lymphoblast colonies in culture, with the same immunologic phenotype or abnormal karyotype as the original leukemic marrow. Four of these patients, including the one who underwent marrow transplantation, relapsed within 2 to 30 months of the abnormal cultures; the other two are still in remission, one of them 30 months after diagnosis. Bone marrow cultures from eight normal controls and from the other seven patients in remission did not yield lymphoblast colonies; all seven of the latter are still in remission. This assay appears to allow detection of small numbers of residual leukemic cells. We conclude that the technique will be valuable in monitoring the efficacy of chemotherapy and allogeneic bone marrow transplantation in acute lymphoblastic leukemia, as well as in evaluating the quality of purged marrow for autologous marrow transplantation.

This article has been cited by other articles:

• Grunberger, T., Demin, P., Rounova, O., Sharfe, N., Cimpean, L., Dadi, H., Freywald, A., Estrov, Z., Roifman, C. M. (2003). Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor. Blood 102: 4153-4158 [Abstract] [Full Text]  
• Nishigaki, H., Ito, C., Manabe, A., Kumagai, M.-a., Coustan-Smith, E., Yanishevski, Y., Behm, F. G., Raimondi, S. C., Pui, C.-H., Campana, D. (1997). Prevalence and Growth Characteristics of Malignant Stem Cells in B-Lineage Acute Lymphoblastic Leukemia. Blood 89: 3735-3744 [Abstract] [Full Text]  
• Roberts, W. M., Estrov, Z., Ouspenskaia, M. V., Johnston, D. A., McClain, K. L., Zipf, T. F. (1997). Measurement of Residual Leukemia during Remission in Childhood Acute Lymphoblastic Leukemia. NEJM 336: 317-323 [Abstract] [Full Text]  
• Greaves, M. (1997). Silence of the Leukemic Clone. NEJM 336: 367-369 [Full Text]  
• Toren, A, Rechavi, G, Nagler, A (1996). Minimal residual disease post-bone marrow transplantation for hemato- oncological diseases. Stem Cells 14: 300-311 [Abstract]  
• Armitage, J. O. (1994). Bone Marrow Transplantation. NEJM 330: 827-838 [Full Text]  
• Uckun, F. M., Kersey, J. H., Haake, R., Weisdorf, D., Nesbit, M. E., Ramsay, N. (1993). Pretransplantation Burden of Leukemic Progenitor Cells as a Predictor of Relapse after Bone Marrow Transplantation for Acute Lymphoblastic Leukemia. NEJM 329: 1296-1301 [Abstract] [Full Text]  
• Kamel-Reid, S, Letarte, M, Sirard, C, Doedens, M, Grunberger, T, Fulop, G, Freedman, M., Phillips, R., Dick, J. (1989). A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. Science 246: 1597-1600 [Abstract]